ArticleJournal of clinical medicine2026

Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.

Wissam Ghusn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.